Carbapenem-resistant Klebsiella pneumoniae (CRKP) (CRKP)

Carbapenem-resistant Klebsiella pneumoniae (CRKP) is a highly problematic Gram-negative bacterial pathogen that has developed resistance to carbapenem antibiotics, which are often the last line of defense for serious infections (CDC, 2019). This resistance is primarily mediated by the production of carbapenemase enzymes, such as the Klebsiella pneumoniae carbapenemase (KPC), which can degrade almost all beta-lactam antibiotics (StatPearls, 2023). CRKP is a major cause of healthcare-associated infections, including pneumonia, bloodstream infections, and urinary tract infections, particularly among patients with compromised immune systems or those requiring invasive medical devices (Nature Reviews Microbiology, 2017). The pathogen's virulence is enhanced by factors such as a thick polysaccharide capsule that prevents phagocytosis and the secretion of siderophores for iron acquisition (PubMed, 2021). Treatment options are severely limited and often involve newer beta-lactam/beta-lactamase inhibitor combinations or older, more toxic drugs like colistin (NIH, 2022). The rapid spread of CRKP is facilitated by the location of resistance genes on mobile plasmids, making it a critical target for infection control and the development of novel antimicrobial strategies (WHO, 2024).

Other names

Carbapenemase-producing Klebsiella pneumoniaeCPKPKPC-producing Klebsiella pneumoniaeCR-KP

Drugs targeting CRKP work through several mechanisms: ceftazidime-avibactam and similar combinations inhibit penicillin-binding proteins while protecting the beta-lactam ring from hydrolysis by carbapenemases; cefiderocol utilizes a siderophore-mediated "Trojan horse" mechanism to enter the periplasmic space and inhibit cell wall synthesis; tigecycline and plazomicin inhibit bacterial protein synthesis by binding to the 30S ribosomal subunit; and colistin acts as a detergent to disrupt the integrity of the bacterial outer membrane (Nature Reviews Disease Primers, 2021; StatPearls, 2023).